Cherry Hill, NJ, United States of America

Bruce L Levine

This inventor holds 33 USPTO granted patents and 18 published patent applications, plus 6 CIPO patents and 13 EPO patents, primarily in Immunotherapy Techniques. Top assignees: University of Pennsylvania, Novartis Ag, The Children's Hospital of Philadelphia. Active years: 2010-2025.

USPTO Granted Patents = 33 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 18)

Average Co-Inventor Count = 5.0

ph-index = 15

Forward Citations = 2,163(Granted Patents)

Company Filing History:

31 out of 2,645

University of Pennsylvania

The Children's Hospital of Philadelphia

patents

4. 2 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

5. 1 out of 5

The Trustees of the University of Pennyslvania

patents

6. 1 out of 16,268

USA as Represented by Secretary of the Navy

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

Immune Cell Expansion

Chronic Lymphocytic Leukemia

Toxicity Management

Regulatory T Cells

Cancer Treatment

Th17 Cells

Transduced T Cells

Rapamycin-Resistant T Cells

Progressive Multifocal Leukoencephalopathy

Immunotherapy

Autoimmune Responses

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240884 - Methods for improving the efficacy and expansion of immune cells (2025-03-04),

2. 11896614 - Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells (2024-02-13),

3. 11648270 - Methods for treating chronic lymphocytic leukemia (CLL) (2023-05-16),

4. 11273219 - Toxicity management for anti-tumor activity of CARs (2022-03-15),

5. 11001805 - ICOS critically regulates the expansion and function of inflammatory human Th17 cells (2021-05-11),

6. 10829735 - Methods for improving the efficacy and expansion of immune cells (2020-11-10),

7. 10603378 - Toxicity management for anti-tumor activity of CARs (2020-03-31),

8. 10273300 - Methods of making chimeric antigen receptor-expressing cells (2019-04-30),

9. 10046008 - Methods for treating chronic lymphocytic leukemia (CLL) (2018-08-14),

10. 9994818 - ICOS critically regulates the expansion and function of inflammatory human Th17 cells (2018-06-12),

11. 9572836 - Methods for assessing the suitability of transduced T cells for administration (2017-02-21),

12. 9540445 - Compositions and methods for treatment of cancer (2017-01-10),

13. 9518123 - Compositions and methods for treatment of cancer (2016-12-13),

14. 9499629 - Use of chimeric antigen receptor-modified T-cells to treat cancer (2016-11-22),

15. 9481728 - Compositions and methods for treatment of cancer (2016-11-01),

Title: The Inventive Journey of Bruce L Levine: Pioneering Immunotherapy Advancements

Introduction:

Bruce L Levine, a pioneering inventor based in Cherry Hill, NJ, has etched his name in the realm of immunotherapy through a remarkable 32 patents. His groundbreaking work has revolutionized the field, particularly in the treatment of chronic lymphocytic leukemia (CLL) and the engineering of chimeric antigen receptor-expressing cells.

Latest Patents:

Levine's recent patents include "Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells," which focuses on enhancing immune effector cells like T cells and NK cells for CAR expression. Additionally, "Methods for treating chronic lymphocytic leukemia (CLL)" demonstrates his commitment to advancing personalized treatments for this condition.

Career Highlights:

Levine's illustrious career has seen him contribute significantly to institutions like the prestigious University of Pennsylvania and the renowned pharmaceutical giant Novartis AG. His relentless pursuit of innovative solutions has earned him recognition as a key figure in the field of immunotherapy.

Collaborations:

Throughout his journey, Bruce L Levine has collaborated with esteemed professionals such as Carl H June and Michael D Kalos. Together, they have synergized their expertise to push the boundaries of immunotherapy and create impactful solutions for patients battling various diseases.

Conclusion:

In conclusion, Bruce L Levine's dedication to innovation and patient-centric research has not only led to numerous patents but has also transformed the landscape of immunotherapy. His contributions continue to inspire future generations of inventors, paving the way for groundbreaking advancements in the treatment of complex medical conditions.